All Press Releases
PILA PHARMA ENTERS INTO AGREEMENT WITH THE CRO GUBRA ON PRECLINICAL TRIALS OF XEN-D0501 IN OBESITY
Malmö, 30 September 2025 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs for treatment of obesity and diabetes based on TRPV1 inhibition, informs investors and others with interest in the space, that it has signed a contract with Danish preclinical Contract Research Organisation, Gubra. The aim is to demonstrate preclinical proof-of-concept of PILA PHARMA's proprietary…
PILA PHARMA TO PARTICIPATE AT THE 61ST EASD DIABETES & OBESITY SCIENTIFIC MEETING, NEXT WEEK 16-19 SEPTEMBER IN VIENNA
Malmö, 08 September 2025 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors and others with interest in the space, of the participation at the 2025 annual congress, hosted by the European Association for Studies of Diabetes (EASD). PILA PHARMA CEO Gustav…
PILA PHARMA: ALL H1 REPORT & INVESTOR INTERVIEWS NOW ONLINE
Malmö, 08 September 2025 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors and others with interest in the space, of the recordings from the last few weeks activities and presentations. 10X Podcast (Recording - Stockholm, Sweden)Recorded Wednesday 27 August 11:00 CET (ENGLISH)CEO…